{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:29:02Z","timestamp":1793946542772,"version":"4.8.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105473","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:29:42Z","timestamp":1783034982000},"page":"105473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neoadjuvant immunotherapy in melanoma: From pathologic response to response-adapted management"],"prefix":"10.1016","volume":"226","author":[{"given":"Xiaohuan","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3150-4382","authenticated-orcid":false,"given":"Renxian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105473_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105473_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40257-024-00852-5","article-title":"Rapidly evolving pre- and post-surgical systemic treatment of melanoma","volume":"25","author":"Augustin","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib3","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105473_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011706","article-title":"Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial","volume":"13","author":"Block","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105473_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12030669","article-title":"Molecular and clinicopathological biomarkers in the neoadjuvant treatment of patients with advanced resectable melanoma","volume":"12","author":"B\u0142o\u0144ski","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105473_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081905","article-title":"Contemporary neoadjuvant therapies for high-risk melanoma: a systematic review","volume":"13","author":"Boulva","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105473_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411849","article-title":"Neoadjuvant immunotherapy: a promising new standard of care","volume":"24","author":"Boydell","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105473_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133344","article-title":"The current state of neoadjuvant therapy in resectable advanced stage melanoma","volume":"15","author":"Bushara","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105473_bib9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13046-024-03153-1","article-title":"Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy","volume":"43","author":"Chan","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105473_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35877","article-title":"Top advances of the year: neoadjuvant immunotherapy in melanoma","volume":"131","author":"Chen","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105473_bib11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41571-022-00630-4","article-title":"Optimal systemic therapy for high-risk resectable melanoma","volume":"19","author":"Eggermont","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115257","article-title":"Neoadjuvant or perioperative immunotherapy for resectable melanoma: the need for biomarkers","volume":"217","author":"Ellebaek","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105473_bib13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41577-025-01222-w","article-title":"Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape","volume":"26","author":"Fallarino","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.suc.2024.11.005","article-title":"Neoadjuvant therapy in melanoma: current evidence and future directions of investigation","volume":"105","author":"Farooq","year":"2025","journal-title":"Surg. Clin. North. Am."},{"key":"10.1016\/j.critrevonc.2026.105473_bib15","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024","volume":"215","author":"Garbe","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105473_bib16","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/s41467-024-45798-8","article-title":"Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial","volume":"15","author":"Hieken","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105473_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115688","article-title":"NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma","volume":"227","author":"Hieken","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105473_bib18","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/2159-8290.CD-23-0352","article-title":"Biomarker-driven personalization of neoadjuvant immunotherapy in melanoma","volume":"13","author":"Hoeijmakers","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105473_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.soc.2024.11.003","article-title":"Neoadjuvant therapy: changes in the management of macroscopic stage III\/resectable stage IV melanoma","volume":"34","author":"Hyngstrom","year":"2025","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"10.1016\/j.critrevonc.2026.105473_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104193","article-title":"Preoperative therapy in melanoma: evolving perspectives in clinical trials","volume":"193","author":"Kakish","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071247","article-title":"Neo-adjuvant therapy for metastatic melanoma","volume":"16","author":"Kuijpers","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105473_bib22","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41591-024-03077-5","article-title":"Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: the randomized phase 2 NeoTrio trial","volume":"30","author":"Long","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105473_bib23","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1200\/JCO.22.02575","article-title":"Neoadjuvant checkpoint immunotherapy and melanoma: the time is now","volume":"41","author":"Long","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib24","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1038\/s41591-025-03967-2","article-title":"Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b\/2 Morpheus-Melanoma trial","volume":"31","author":"Long","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105473_bib25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41571-023-00760-3","article-title":"Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma","volume":"20","author":"Lucas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jamaoncol.2023.7333","article-title":"Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 therapy in high-risk resectable melanoma: a pooled analysis","volume":"10","author":"Mangla","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105473_bib28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.annonc.2024.05.002","article-title":"Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma","volume":"35","author":"Menzies","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/CCO.0000000000001119","article-title":"Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?","volume":"37","author":"Meyers","year":"2025","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26062427","article-title":"Opportunities for discovery using neoadjuvant immune checkpoint blockade in melanoma","volume":"26","author":"Nair","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105473_bib31","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/bjd\/ljaf268","article-title":"Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III\/IV melanoma: a nationwide real-life study in France (NEOMEL)","volume":"194","author":"Nardin","year":"2026","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115485","article-title":"Neoadjuvant immunotherapy for patients with resectable stage III\/IV cutaneous melanoma - A Swedish retrospective real-world study (NEO-MEL)","volume":"224","author":"Nelson","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105473_bib33","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1245\/s10434-025-18475-3","article-title":"International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma","volume":"33","author":"Novis","year":"2026","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105473_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006947","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0","volume":"11","author":"Pavlick","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105473_bib36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11864-020-0700-z","article-title":"Neoadjuvant immunotherapy for locally advanced melanoma","volume":"21","author":"Pelster","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib37","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.annonc.2021.03.006","article-title":"Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma","volume":"32","author":"Rawson","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.annonc.2025.10.1237","article-title":"Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma","volume":"37","author":"Rawson","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115141","article-title":"Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: comparison of 3-year data from PRADO and OpACIN-neo","volume":"214","author":"Reijers","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105473_bib40","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/1744666X.2023.2248392","article-title":"Clinical updates in neoadjuvant immunotherapy for melanoma before surgery","volume":"20","author":"Saad","year":"2024","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib41","doi-asserted-by":"crossref","first-page":"8958","DOI":"10.1245\/s10434-025-18314-5","article-title":"Single-dose neoadjuvant pembrolizumab in resectable metastatic melanoma","volume":"32","author":"Shafique","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib42","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.annonc.2023.06.006","article-title":"Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III\/IV cutaneous melanoma","volume":"34","author":"Sharon","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14737140.2025.2474733","article-title":"Overcoming common emerging barriers to effective neoadjuvant immunotherapies","volume":"25","author":"Sokol","year":"2025","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.critrevonc.2026.105473_bib44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/14737140.2020.1760847","article-title":"Neoadjuvant treatments in patients with high-risk resectable stage III\/IV melanoma","volume":"20","author":"Spagnolo","year":"2020","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.critrevonc.2026.105473_bib45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/PPO.0000000000000706","article-title":"Treatment of Stage III resectable melanoma-adjuvant and neoadjuvant approaches","volume":"30","author":"Tarhini","year":"2024","journal-title":"Cancer J."},{"key":"10.1016\/j.critrevonc.2026.105473_bib46","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2023.01.004","article-title":"Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma","volume":"182","author":"van","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105473_bib47","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","article-title":"Learning from clinical trials of neoadjuvant checkpoint blockade","volume":"26","author":"Versluis","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105473_bib48","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105473_bib49","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00262-025-04094-0","article-title":"Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures","volume":"74","author":"Wijnen","year":"2025","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:48:34Z","timestamp":1793944114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":49,"alternative-id":["S1040842826003604"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105473","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant immunotherapy in melanoma: From pathologic response to response-adapted management","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105473"}}